The first is, I'm unconvinced with the ability to identify all the harmful products that are relevant to this discussion. I'm unconvinced with the quantitative and qualitative assessment of the drugs that we're interested in, unconvinced—as my colleague, the Hon Simon Bridges has said—with the evidence. Certainly, it would seem to cut both ways, but not a clear benefit to this sort of process—and I'd say that it's especially for those who are regular users. Arbitrarily, those who are first-time users—conjecturally—may well have some benefit. Again, conjecturally. But, certainly for those who are regular users, no clear benefit that they change behaviour once they've been through a pill testing process and been notified of what the contents are. 